This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Intercept Pharmaceuticals.
Reference
Morgan A, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. European Journal of Health Economics : 22 Mar 2021. Available from: URL: https://doi.org/10.1007/s10198-020-01256-y
Rights and permissions
About this article
Cite this article
Non-alcoholic steatohepatitis substantial burden in the UK. PharmacoEcon Outcomes News 875, 18 (2021). https://doi.org/10.1007/s40274-021-7597-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7597-z